PRLD
Prelude Therapeutics Inc
3.70$
-3.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | – | – | 100.0% | 100.0% | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 9.7% | – | – | – | 12.2% | – | – | 6.5% | 7.4% | 8.5% | – | – | |
| – | -9.7% | – | – | 100.0% | 100.0% | – | – | 100.0% | 100.0% | 91.5% | 100.0% | 98.3% | |
| – | 885.9% | – | – | 981.9% | 790.5% | – | – | 334.0% | 319.0% | 297.0% | 282.8% | 309.6% | |
| – | 205.8% | – | – | 264.0% | 155.3% | – | – | 80.2% | 88.6% | 112.6% | 88.1% | 90.9% | |
| – | 1,082.0% | – | – | 1,245.9% | 945.8% | – | – | 414.1% | 407.6% | 401.0% | 370.9% | 398.8% | |
| – | -1,091.7% | – | – | -1,145.9% | -845.8% | – | – | -314.1% | -307.6% | -309.5% | -270.9% | -300.6% | |
| – | 40.8% | – | – | – | – | – | – | – | – | – | – | – | |
| – | -966.0% | – | – | -1,075.7% | -718.3% | – | – | -303.5% | -291.8% | -226.7% | -244.1% | -269.7% | |
| – | 48.9% | – | – | – | – | – | – | – | – | – | – | – | |
| – | -966.0% | – | – | -1,075.7% | -718.3% | – | – | -303.5% | -291.8% | -226.7% | -244.1% | -269.7% | |
| – | -956.3% | – | – | -1,062.2% | -706.1% | – | – | -296.9% | -284.4% | -218.2% | -237.9% | -262.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.